AtaiBeckley (ATAI) Chief Accounting Officer Anne Nagengast Sells 3.19M Shares

What Happened
Anne Nagengast, Chief Accounting Officer of AtaiBeckley Inc. (ATAI), reported dispositions on 2026-09-11 totaling 3,187,996 shares (combination of common stock and derivative-based interests) in connection with the company’s merger with Eli Lilly. Under the merger terms each outstanding share converted into $6.75 in cash plus one contingent value right (CVR) per share; the cash portion for these shares equals about $21.52 million. The CVRs represent the right to receive up to $2.50 per CVR (aggregate potential up to ~ $7.97 million), subject to achievement of specified milestones and applicable tax withholding.

Key Details

• Transaction date: 2026-09-11 (merger effective date and Form 4 filing date). Transaction code: D (Disposition to issuer).
• Total shares disposed: 3,187,996 (sum of listed common and derivative-related dispositions).
• Cash consideration per share: $6.75; estimated cash received ≈ $21,518,973 (before tax withholding).
• Contingent consideration: 1 CVR per share, up to $2.50 per CVR (aggregate potential ≈ $7,969,990), contingent on clinical/regulatory milestones.
• Many listed line items are derivative-related dispositions (options and RSUs converted/cancelled per Merger terms). See footnotes F1–F4 describing the merger and conversion mechanics.
• Filing appears timely (filed with period of report 2026-09-11). The Form 4 reports dispositions resulting from the merger; it does not list any retained common-stock holdings post-conversion in this filing.

Context

• These were not open-market sales but merger-driven conversions: outstanding stock, options and RSUs were canceled or converted into cash and CVRs per the merger agreement (options converted into cash equal to (shares × (6.75 − exercise price)) and RSUs converted into cash equal to (shares × 6.75), each also receiving CVRs).
• CVRs are contingent payments tied to future milestones — not guaranteed cash today.
• Merger-driven dispositions are routine in acquisitions and reflect deal consideration rather than a typical insider market sale; they should be interpreted differently than discretionary insider purchases or sales.